Watch the replay of the HAS-PFUE Symposium "Together for HTA in Europe"

The entry into force of the European regulation on health technology assessment marks the start of a new era. It heralds greater cooperation between agencies responsible for these assessments in different European states, the aim being to facilitate access to innovations with a clinical benefit, in the interest of patients. How can this objective be met without departing from the stringent quality, safety and transparency standards required for any health technology assessment? What are the factors for success, both in times of crisis and in the long term?

This international, participative conference, organised as part of the French Presidency of the European Union, sets out to shed light on these key public health issues.

 

Agenda

10:30 a.m. - Opening

• Dominique Le Guludec, President, Haute Autorité de santé (HAS), Co-Chair, Heads of Agencies Group (HAG)
• Olivier Véran, French Minister of Health and Solidarity
• Andrzej Rys, Director, Health Systems, Medical Products and Innovation, Directorate-General for Health and Food Safety (DG SANTE), European Commission

 

11:00 a.m. - Keynote lecture : European HTA in a global context

• Valérie Paris, Chair of the Economic and Public Health Committee, Board member, HAS

Health technology assessment has a long history and has established itself as a critical tool for clarifying price and reimbursement decisions in many countries. The decision of European countries to produce a joint clinical assessment answer to the needs of many stakeholders including governments, industry and patients. What impact will this reform have in Europe and beyond?

11:15 a.m. - Cooperation of HTA agencies within Europe: from sharing experience to carrying out joint assessments

How was the new European regulation on HTA developed? What are its objectives? What does it provide for? How did the voluntary cooperation between European HTA agencies foreshadowed the system of the regulation? What are the roles and expectations of patients and industry?

Focus on the challenges and issues of the new European HTA regulation

• Tiemo Wölken, Member of the European Parliament

Implementation of the European HTA regulation

• Flora Giorgio, Deputy Head of Unit B6 Medical Devices and HTA, Directorate-General for Health and Food Safety (DG SANTE), European Commission
  Flora Giorgio's presentation

Contribution of European cooperation in HTA

• Marcus Guardian, Chief Operating Officer, European Network for Health Technology Assessment (EUnetHTA)

Patient and public involvement

• François Houÿez, Treatment Information and Access Director, EURORDIS

Participation of pharmaceutical companies

• Ansgar Hebborn, Chair, HTA Working Group, European Federation of Pharmaceutical Industries and Associations (EFPIA)

Round table

 

2:00 p.m. - The challenge of methods for HTAs in Europe

Contribution of the EUnetHTA 21 consortium
How are the European HTA agencies and the EUnetHTA 21 consortium preparing for the implementation of this new European regulation? The example of Germany and France.

• Pierre Cochat, Chair of the Transparency Committee, Board member, HAS
• Stefan Lange, Deputy Director, Institute for Quality and Efficiency in Health Care (IQWIG)

Stakes of HTA method
What kind of cooperation with the research community in the future? What impact on research data? What contributions can academics make to ensure that the new evaluation methods are properly taken into account in European productions?

• Florian Naudet, Professor, University Hospital of Rennes
• Rosanna Tarricone, Associate Dean, Bocconi School of Management

Focus - Artificial intelligence and health technologies: a challenge for assessment

• Isabelle Adenot, Chair of the Medical Technology and Interventional Procedure Committee, Board member, HAS

Round table

 

3:00 p.m. - Innovation in the face of a world health crisis: the role of HTAs in the EU

The HTA agencies' perspective

• Rui Santos Ivo, President, National Authority of Medicines and Health Products (INFARMED), Chair, HAG

The industry's perspective

• Alexander Natz, Secretary General, European Confederation of Pharmaceutical Entrepreneurs (EUCOPE)

Round Table

• Francis Arickx, Head of the Directorate Reimbursement of Medicines and Pharmaceutical Policy, RIZIV-INAMI
• Michaël Berntgen, Head of Scientific Evidence Generation Department - Human medicines division, European Medicines Agency (EMA)
• Alexander Natz, Secretary General, EUCOPE
• Andrzej Rys, Director for Health Systems, Medical Products and Innovation, Directorate-General for Health and Food Safety (DG SANTE), European Commission
• Rui Santos Ivo, President, INFARMED, Chair, HAG
• Valentina Strammiello, Head of Programmes, European Patient Forum (EPF)

 

4:00 p.m. - Closing 

• Rui Santos Ivo, President of INFARMED, Chair of the HAG
• Agneta Karlsson, Director General ofTLV, Co-Chair of the HAG
• Dominique Le Guludec, President of the HAS, Co-Chair of the HAG

> Consult the participant file

*This event is not organised by the French government. However, it is authorised by the Government to use the emblem of the French Presidency of the Council of the European Union.